1. Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells
   John S. Schardt et al, 2017, Mol. Pharmaceutics CrossRef
2. A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer
   Chin-Hsien Tsai et al, 2017, Front. Pharmacol. CrossRef
3. STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization
   Yuichi Kitai et al, 2017, J. Biol. Chem. CrossRef
4. An electrochemical cytosensor for ultrasensitive detection of cancer cells using modified graphene–gold nanostructures
   Amir Yadegari et al, 2017, RSC Adv. CrossRef
5. Beyond Androgen Deprivation
   Mark F. McCarty et al, 2014, Integr Cancer Ther CrossRef
6. Zerumbone Regulates DNA Repair Responding to Ionizing Radiation and Enhances Radiosensitivity of Human Prostatic Cancer Cells
   Pai-Kai Chiang et al, 2017, Integr Cancer Ther CrossRef
7. In vitro modeling of HER2-targeting therapy in disseminated prostate cancer
   JENNIE ANDERSSON et al, 2014 CrossRef
8. Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients
   JENNIE ANDERSSON et al, 2015 CrossRef
9. Posttranslational Modification of the Androgen Receptor in Prostate Cancer
   Travis Van der Steen et al, 2013, IJMS CrossRef
10. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
    Jodi M Saunus et al, 2015, J. Pathol. CrossRef
11. ErbB-2 signaling in advanced prostate cancer progression and potential therapy
    Dannah R Miller et al, 2019 CrossRef
12. Cell mates: paracrine and stromal targets for prostate cancer therapy
    Pavel Sluka et al, 2013, Nat Rev Urol CrossRef
13. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial–mesenchymal transition
    Lauren N Hendrix et al, 2013, Expert Review of Endocrinology & Metabolism CrossRef
14. Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity
    Clara Panosa et al, 2013, PLoS ONE CrossRef
15. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer
    Pavlos Msaouel et al, 2013, Expert Opinion on Investigational Drugs CrossRef
16. The hurdle of antiandrogen drug resistance: drug design strategies
    Jill A Trendel, 2013, Expert Opinion on Drug Discovery CrossRef
17. A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
    Sebastien Taurin et al, 2014, BioMed Research International CrossRef
18. Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development
    Juliana Inês Santos et al, 2014, Tumor Biol. CrossRef
19. Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor
    Sakthivel Muniyan et al, 2014, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
20. Targeting the relaxin hormonal pathway in prostate cancer
    Anton Neschadim et al, 2015, Int. J. Cancer CrossRef
21. Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma
    Shokouh Taghipour Zahir et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
22. Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
    Adriana Blancafort et al, 2015, PLoS ONE CrossRef
23. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
    Arndt Katzenwadel et al, 2015, Cancer Lett. CrossRef
24. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib
    Eirik Sundby et al, 2015, European Journal of Pharmaceutical Sciences CrossRef
25. Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling
    Jimeng Hu et al, 2016, Anti-Cancer Drugs CrossRef
26. SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway
    Yu-Jeong Choi et al, 2016, BMC Complement Altern Med CrossRef
27. null
    Giuseppe Tridente, 2017 CrossRef
28. Correlation of gleason grading and prognostic immunohistochemistry markers (human epidermal growth factor receptor 2/neu and androgen receptor) in prostatic core needle biopsy: A study in a tertiary care center
    Utsha Senapati et al, 2019, Indian J Med Paediatr Oncol CrossRef
29. Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells
    Jianfang Zhao et al, 2016, Oncotarget CrossRef
30. Regulation of ERBB3/HER3 signaling in cancer
    Kalpana Mujoo et al, 2014, Oncotarget CrossRef
31. Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC)
    Bhavana Jonnalagadda et al, 2020, Life Sciences CrossRef
32. The G Protein–Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3
    Terry W. Moody et al, 2020, J Mol Neurosci CrossRef
33. Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145
    Raik Schneider et al, 2021, Radiat Oncol CrossRef
34. The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
    Guilherme Peixoto et al, 2021, Mol Clin Oncol CrossRef
35. Synthesis and biological evaluation of 3,5‐diaryl‐pyrazole derivatives as potential antiprostate cancer agents
    Derya Anil et al, 2021, Arch Pharm CrossRef
36. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent
    Ritu Ojha et al, 2021, J. Med. Chem. CrossRef
37. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
    Lauren M. Lucas et al, 2022, Pharmacol Rev CrossRef
38. Evaluation of Anticancer and Epidermal Growth Factor Receptor Inhibition Activity by Benzochromeno Pyrimidin Derivatives in Three Human Cancer Cell Lines
    Razieh Mohammadian et al, 2022, MC CrossRef
39. Erlotinib‐Modified BODIPY Photosensitizers for Targeted Photodynamic Therapy
    Elif Yıldız Gül et al, 2022, ChemMedChem CrossRef
40. Epiregulin expression and secretion is increased in castration-resistant prostate cancer
    Marc Wiesehöfer et al, 2023, Front. Oncol. CrossRef
41. Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?
    Pedro A. Martínez-Carpio, 2023, Cutaneous and Ocular Toxicology CrossRef
42. Synthesis and In Vitro Evaluation as Potential Anticancer and Antioxidant Agents of Diphenylamine-Pyrrolidin-2-one-Hydrazone Derivatives
    Irma Zubrickė et al, 2023, IJMS CrossRef
43. Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications
    Taiga Maemoto et al, 2024 CrossRef
44. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells
    Carlos Eduardo Fonseca-Alves et al, 2024, PLoS ONE CrossRef
45. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer
    Lufeng Zheng et al, 2024, J. Med. Chem. CrossRef